Gonadorelin Acetate
Evidence: B — Meaningful Human EvidenceHormone / Fertility
Evidence Snapshot
Regulatory Context
FDA records show historical approval of Lutrepulse (gonadorelin acetate) for induction of ovulation in hypothalamic amenorrhea. Current U.S. marketing availability and product status require separate verification before publication.
Research Takeaway
Gonadorelin is synthetic native gonadotropin-releasing hormone (GnRH), a decapeptide that stimulates pituitary LH and FSH release when delivered in a physiologic pulsatile pattern; it is distinct from long-acting GnRH agonists such as leuprolide and nafarelin.
Evidence boundary: Continuous or long-acting GnRH-agonist exposure can produce different and even suppressive endocrine effects, so these drugs must not be conflated.
See all 6 evidence claims →Quick Summary
Gonadorelin acetate is a synthetic GnRH salt studied and historically used in pulsatile reproductive-endocrine therapy and diagnostic stimulation testing.
Mechanism & Research Overview
Gonadorelin is synthetic gonadotropin-releasing hormone. Pulsatile exposure can stimulate pituitary LH and FSH secretion, while a diagnostic bolus can test pituitary gonadotroph responsiveness.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
Gonadorelin is synthetic native gonadotropin-releasing hormone (GnRH), a decapeptide that stimulates pituitary LH and FSH release when delivered in a physiologic pulsatile pattern; it is distinct from long-acting GnRH agonists such as leuprolide and nafarelin.
Does not establish
Evidence boundary: Continuous or long-acting GnRH-agonist exposure can produce different and even suppressive endocrine effects, so these drugs must not be conflated.
Supported
Pulsatile native GnRH has human evidence for restoring gonadotropin secretion and gonadal function in selected patients with hypothalamic hypogonadotropic hypogonadism.
Does not establish
Evidence boundary: These results depend on diagnosis and pulsatile delivery and do not establish benefit for routine TRT adjunct use or nonspecific testosterone enhancement.
Supported
FDA compounding documents identify gonadorelin acetate as a substance that has been a component of FDA-approved drug products, but this frozen package does not establish the availability of a currently marketed FDA-approved human gonadorelin finished product as of August 11, 2026.
Does not establish
Evidence boundary: Historical approved-drug status must not be simplified into a claim that every current compounded gonadorelin product is FDA-approved.
Supported
The safety and endocrine effects of gonadorelin are strongly dependent on delivery pattern, because pulsatile stimulation and sustained GnRH-receptor stimulation can have materially different physiological consequences.
Does not establish
Evidence boundary: This mechanistic distinction does not quantify the adverse-event profile of any specific compounded product.
Supported
Evidence from pulsatile GnRH treatment of diagnosed hypothalamic hypogonadism does not establish gonadorelin as a proven substitute for hCG in men receiving exogenous testosterone.
Does not establish
Evidence boundary: The absence of direct equivalence evidence prevents transferring fertility or testicular-maintenance claims between these therapies.
Supported
Only named clinical-study or historical approved-label dosing may appear as Study/Trial Dosing; consumer pump schedules, TRT-adjunct dosing, reconstitution, or injection guidance are prohibited.
Does not establish
Evidence boundary: Historical clinical dosing is descriptive evidence, not a current individualized recommendation.
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Safety Consideration
Rare anaphylaxis after intravenous gonadorelin acetate has been reported.Safety Consideration
Pulsatile fertility treatment can produce multiple pregnancy and requires specialist monitoring.Safety Consideration
Continuous and pulsatile GnRH exposure can have different endocrine effects; they must not be conflated.
Research Areas Being Studied
Research areas discussed on this page reflect the Hormone / Fertility category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
No Human Study Findings Listed Yet
See preclinical, regulatory, and review sources below.
Study Tables by Evidence Type
No Sources Listed Yet
Human, preclinical, regulatory, and review sources will appear here as they are added.
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
Educational information only. This page summarizes published and official research and does not provide medical advice, a recommendation, or instructions for human use.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Content pending review. Last updated 2026-07-26.
Follow research updates for Gonadorelin Acetate
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.